Application of olaparil combined with ML264 in preparation of drug-resistant ovarian cancer drugs
Through the combination of olaparib and KLF5 inhibitor ML264, the problem of ovarian cancer resistance to PARP inhibitors has been solved, significantly improved the sensitivity and survival of ovarian cancer to treatment, and provided a new treatment plan .
Patent Information
- Application Number
- CN202411121207.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-19
AI Technical Summary
The existing PARPi has drug resistance problems in the treatment of ovarian cancer, and more than 40% of patients with BRCA1/2 defects do not respond to PARPi, resulting in poor treatment results.
Using olaparib combined with KLF5 inhibitor ML264, it was verified through cell and animal experiments that it can induce apoptosis and growth inhibition of PARP inhibitors at low concentrations, which significantly synergistically improves the PARP inhibitors in ovarian cancer. Sensitivity.
The combination of olaparib and ML264 significantly reduces the resistance of ovarian cancer to PARP inhibitors, increases the patient's sensitivity to treatment, and effectively reduces tumor burden and prolongs the patient's survival.
Smart Images

Figure CN118976028A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and specifically relates to the application of Olaparib combined with ML264 in the preparation of drug-resistant ovarian cancer drugs. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] The incidence of ovarian cancer ranks third among gynecological malignancies, but its mortality rate ranks first, and it is known as the "king of gynecological cancers." In recent years, molecular targeted therapy, as a new treatment for ovarian cancer, has achieved a number of breakthrough research results. Among them, poly(ADP-ribose) polymerase inhibitors (PARPi) have brought new hope for the targeted treatment of ovarian cancer. Currently, PARPi represented by Olaparib and Niraparib have been widely approved for the first-line maintenance treatment of ovarian cancer patients with BRCA mutations and HRD(+) and the maintenance treatment of some platinum-sensitive relapsed patients.
[0004] With the large-scale use of PARPi, while a large number of patients benefit from it, the problem of PARPi resistance has gradually emerged. More than 40% of BRCA1 / 2-deficient patients do not respond to PARPi, and homologous recombination repair (HRR) has become the main cause of PARPi resistance. DNA replication fork protection is also involved in PARPi resistance in BRCA1 / 2-deficient cells and patients. At the same time, reversal mutations, epigenetic modifications, restoration of ADP-ribosylation, and pharmacological changes can also lead to PARPi resistance. Summary of the invention
[0005] In view of the deficiencies in the above-mentioned prior art, the inventors, after long-term technical and practical exploration, provide the use of Olaparib combined with ML264 in the preparation of drug-resistant ovarian cancer drugs. Specifically, the present invention verifies through cell and animal experiments that the KLF5 inhibitor ML264 can induce apoptosis and growth inhibition of ovarian tumor cells resistant to PARP inhibitors in vitro at low concentrations. The combination of Olaparib and ML264 shows a significant synergistic effect in the treatment of drug-resistant ovarian cancer. Based on the above research results, the present invention is completed.
[0006] In order to achieve the above technical objectives, the present invention adopts the following technical solutions:
[0007] The first aspect of the present invention provides the use of Olaparib in combination with ML264 in any one or more of the following:
[0008] a) preparing products that promote apoptosis of tumor cells;
[0009] b) preparing products that inhibit tumor growth;
[0010] c) preparing products that increase the sensitivity of tumors to PARP inhibitors;
[0011] d) Preparation of products for tumor treatment.
[0012] The tumor may be ovarian cancer, and may further be ovarian cancer resistant to PARP inhibitors.
[0013] The second aspect of the present invention provides a composition, wherein the active ingredients of the composition include at least the above-mentioned Olaparib and ML264.
[0014] The composition has any one or more of the following applications:
[0015] a) Promote apoptosis of tumor cells;
[0016] b) inhibiting tumor growth;
[0017] c) Increase tumor sensitivity to PARP inhibitors;
[0018] d)Tumor treatment.
[0019] The third aspect of the present invention provides a method for treating ovarian cancer resistant to PARP inhibitors, comprising administering the above-mentioned Olaparib and ML264 or the above-mentioned combination to a subject.
[0020] Compared with the existing technical solutions, the above one or more technical solutions have the following beneficial effects:
[0021] The above technical scheme has been proven through cell experiments that Olaparib and ML264 have a synergistic inhibitory effect on ovarian cancer resistant to PARP inhibitors. ML264 can effectively reduce the resistance of ovarian cancer to PARP inhibitors such as Olaparib and promote apoptosis of ovarian cancer cells. Animal experiments have shown that the drug combination of Olaparib and ML264 can significantly increase the sensitivity of patients with ovarian cancer resistant to PARP inhibitors to PARP inhibitors and significantly reduce their tumor burden.
[0022] In summary, the above technical solution provides a novel and effective method for treating ovarian cancer, especially ovarian cancer resistant to PARP inhibitors. It provides a new combination drug regimen for patients with ovarian cancer resistant to PARP inhibitors, which helps to prolong the survival of patients, and therefore has important clinical significance and social value. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0024] Figure 1 The relative cell survival rates of ovarian cancer cell lines A2780-olaR and SKOV3-olaR treated with olaparib, ML264, and olaparib combined with ML264 gradient in the present invention (A and C). The control group (DMSO), olaparib (50uM), ML264 (30nM), and olaparib combined with ML264 treated ovarian cancer cell line A2780-olaR (B). The apoptosis rate of the control group (DMSO), olaparib (30uM), ML264 (30nM), and olaparib combined with ML264 treated ovarian cancer cell line SKOV3-olaR (D).
[0025] Figure 2 The synergistic index scores (A and C) obtained by treating ovarian cancer cell lines A2780-olaR and SKOV3-olaR with olaparib and ML26 at different drug concentrations for 72 h in the examples of the present invention, and the scatter plots (B and D) of the relationship between the inhibition rate and the drug synergistic index (CI).
[0026] Figure 3 The effects of different drugs on the tumor load of mice after inoculation of A2780-olaR in the animal model in the present invention are shown in the following figure. (A) Olaparib was injected intraperitoneally at a concentration of 50 mg / kg, and there was no significant difference with the DMSO control group. ML264 was injected intraperitoneally at a concentration of 10 mg / kg, once every 2 days; (B) The weight of the tumor in mice in different treatment groups; (C) The volume growth curve of the tumor in mice in different treatment groups; (D) Tunel staining of the mouse tumor tissue and the statistical graph of the apoptosis results. DETAILED DESCRIPTION
[0027] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.
[0028] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.
[0029] As mentioned earlier, with the large-scale use of PARPi such as Olaparib, while a large number of patients benefit from it, the problem of PARPi resistance has gradually emerged.
[0030] In view of this, the present invention discovered the key transcription factor KLF5 in high-grade serous PARP inhibitor-resistant ovarian cancer based on the differential expression of RNA-seq data analysis of PARP inhibitor-resistant and sensitive ovarian cancer cells. As a member of the KLF family, KLF5 regulates the expression of a large number of new target genes and participates in multiple cellular functions. Recent studies have shown that KLF5 is abnormally expressed in a variety of solid tumors, such as breast cancer, prostate cancer, colon cancer, non-small cell lung cancer and esophageal squamous cell carcinoma. KLF5 expression is abnormally increased in high-grade serous ovarian cancer, and its high expression indicates a poor prognosis for ovarian cancer patients.
[0031] The KLF5 inhibitor ML264 (CAS: 1550008-55-3) has excellent drug metabolism and pharmacokinetic characteristics. Its first-pass metabolism is highly stable and it also shows 47% oral bioavailability in mice. It does not inhibit the activity of cytochrome P450 isoenzymes. In addition, ML264 is inactive against 47 selected kinases and 67 protein targets of therapeutic / toxicological significance, and has potential high safety in terms of drug-drug interactions.
[0032] Based on the above, the present invention proposes a new method of combining Olaparib with ML264 to treat PARPi-resistant ovarian cancer, which brings new hope for patients with PARP inhibitor-resistant ovarian cancer.
[0033] Therefore, in a typical embodiment of the present invention, the use of Olaparib combined with ML264 in any one or more of the following is provided:
[0034] a) preparing products that promote apoptosis of tumor cells;
[0035] b) preparing products that inhibit tumor growth;
[0036] c) preparing products that increase the sensitivity of tumors to PARP inhibitors;
[0037] d) Preparation of products for tumor treatment.
[0038] In the application, the molar ratio of Olaparib to ML264 is 5-100:0.005-1.5.
[0039] The tumor may be ovarian cancer, and may further be drug-resistant ovarian cancer, wherein the drug-resistant ovarian cancer is ovarian cancer resistant to PARP inhibitors.
[0040] In the above d), the tumor treatment at least manifests itself in: promoting apoptosis of ovarian cancer tumor tissue and / or prolonging the survival of ovarian cancer patients.
[0041] The product can be a drug or an experimental reagent, and the experimental reagent is specifically a common experimental reagent for non-medical use, so that it can be used for basic research on ovarian cancer, especially PARPi-resistant ovarian cancer.
[0042] In the present invention, the PARP inhibitors include at least Olaparib and Niraparib, among which Olaparib is preferred.
[0043] According to the present invention, when the product is a medicine, the medicine may further include at least one pharmaceutically inactive ingredient.
[0044] The inactive ingredients of the drug can be carriers, excipients and diluents commonly used in pharmacy. Moreover, according to the usual methods, the drug can be made into oral preparations, external preparations, suppositories and sterile injection solutions in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, sprays, etc.
[0045] The non-drug active ingredients such as carriers, excipients and diluents that may be included are well known in the art, and those skilled in the art can determine whether they meet clinical standards.
[0046] In another specific embodiment of the present invention, the carrier, excipient and diluent include but are not limited to acetate, phosphate, citrate, serum protein, gelatin, polyvinyl pyrrolidone, glycine, glutamine, asparagine, histidine, arginine lactose, glucose, sucrose, sorbitol, mannitol, trehalose, sodium chloride, water, methyl hydroxybenzoate, propyl hydroxybenzoate, magnesium stearate and mineral oil.
[0047] In another specific embodiment of the present invention, the medicine of the present invention can be administered to the body in a known manner. For example, it can be delivered systemically by vein. It can be optionally administered via intravenous, transdermal, intranasal, mucosal or other delivery methods. Such administration can be carried out via a single dose or multiple doses. It will be appreciated by those skilled in the art that the actual dose to be administered in the present invention can vary greatly depending on a variety of factors, such as target cells, biological types or their tissues, the general condition of the subject to be treated, the route of administration, the mode of administration, etc.
[0048] In another specific embodiment of the present invention, the drug administration subjects can be humans and non-human mammals, such as rats, mice, rabbits, monkeys, orangutans, etc.
[0049] In another specific embodiment of the present invention, a composition is provided, wherein the active ingredients of the composition at least include the above-mentioned Olaparib and ML264.
[0050] The molar ratio of Olaparib to ML264 is 5-100:0.005-1.5.
[0051] The composition has any one or more of the following applications:
[0052] a) Promote apoptosis of tumor cells;
[0053] b) inhibiting tumor growth;
[0054] c) Increase tumor sensitivity to PARP inhibitors;
[0055] d)Tumor treatment.
[0056] In the above d), the tumor treatment at least manifests itself in: promoting apoptosis of ovarian cancer tumor tissue and / or prolonging the survival of ovarian cancer patients.
[0057] The tumor may be ovarian cancer, and may further be drug-resistant ovarian cancer, wherein the drug-resistant ovarian cancer is ovarian cancer resistant to PARP inhibitors.
[0058] In another specific embodiment of the present invention, a method for treating ovarian cancer resistant to PARP inhibitors is provided, the method comprising administering the above-mentioned Olaparib and ML264 or the above-mentioned combination to a subject.
[0059] The present invention is further described below in conjunction with specific examples, which are only for explaining the present invention and do not limit its content. Any simple modification, equivalent changes and modifications made to the implementation methods based on the technical essence of the present invention are within the scope of the technical solution of the present invention.
[0060] Example
[0061] Research Methods
[0062] 1.CCK8 activity detection
[0063] Ovarian cancer cells were seeded in a 96-well plate (1000 cells per well), treated with gradient concentrations of olaparib or ML264, 10% CCK-8 solution was added to each well, and an equal amount of solution was added to the blank well as a control. The plates were incubated at 37°C for 2 hours, and the absorbance of the samples was measured at 450 nm using an enzyme reader.
[0064] 2. Flow Cytometry
[0065] Cell apoptosis was detected by flow cytometry. No EDTA was added when digesting the cells. The cells were washed with PBS and resuspended in 1X binding buffer. The cells were stained with 5 μl FITC-Annexin V and 5 μl propidium iodide (PI) for 10 min. The proportion of apoptotic cells was detected using a BD FACSCalibur flow cytometer, and data were analyzed using Flow Jo V10.4.
[0066] 3. CI index calculation
[0067] A2780-olaR and SKOV3-olaR cells were treated with olaparib and ML264 at different drug concentrations. OD values at 450 wavelength were measured by CCK8 assay 72 hours after administration. Drug synergy analysis was performed by CompuSyn software 1.2.0 (ComboSyn Incorporated; http: / / www.combosyn.com). The combination effect was defined by the combination index (CI) value, with synergistic effect (<1), additive effect (=1) and antagonistic effect (>1).
[0068] 4. A2780-olaR Mouse Tumor Model
[0069] 1*10 6 Ovarian cancer cells were subcutaneously injected under the armpits on both sides of BALB / c nude mice. A2780-olaR cells were subcutaneously inoculated into 24 nude mice and randomly divided into 4 groups (6 mice in each group). When the tumor diameter reached 5mm, the corresponding treatment was given: normal saline (10% DMSO), Olaparib (50mg / kg), ML264 (10mg / kg), Olaparib and ML264 combined (50mg / kg+10mg / kg). The drug was administered intraperitoneally once every 2 days, and the tumor volume and weight were measured. The mice were then euthanized, and the tumors were dissected, photographed, weighed and measured. The maximum diameter of the tumor is less than 15mm.
[0070] 5. Tunel test
[0071] Mouse tumor tissues were prepared into paraffin sections, and apoptosis detection was performed according to the instructions of the TMR (Red) Tunel apoptosis detection kit. Tissue sections were dewaxed, treated with proteinase K, and washed 3 times with PBS. After equilibration with the balance solution, the sections were incubated with TdT incubation buffer at 37°C for 1 hour, and then washed 3 times with PBS. After DPAI staining, the sections were immediately sealed with an anti-fluorescence quencher and observed under a fluorescence microscope.
[0072] Study Results
[0073] The study found that low concentrations of ML264 can induce apoptosis and growth inhibition of PARP inhibitor-resistant ovarian tumor cells in vitro. Low concentrations of ML264 can induce apoptosis of ovarian cancer cells in vitro for 72 hours. Figure 1-2 It can be seen that the combination of the two produces a significant synergistic anti-tumor effect.
[0074] like Figure 3 As shown, in the mouse PARP inhibitor-resistant tumor model, the intraperitoneal injection of olaparib at a concentration of 50 mg / kg showed no significant difference from the DMSO control group. Intraperitoneal injection of ML264 at a concentration of 10 mg / kg, once every 2 days, can significantly reduce the tumor burden of mice. The combined use of olaparib and ML264 can significantly increase the sensitivity of PARP inhibitor-resistant ovarian cancer patients to PARP inhibitors and significantly reduce the tumor burden of mice.
[0075] In summary, the present invention provides a novel and effective method for treating ovarian cancer, especially PARPi-resistant ovarian cancer. The combined use of Olaparib and ML264 will bring new treatment options for ovarian cancer patients, and is expected to improve the treatment effect of ovarian cancer and improve the quality of life of ovarian cancer patients.
[0076] The above description is only the preferred embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims
1. The use of Olaparib combined with ML264 in any one or more of the following: a) preparing products that promote apoptosis of tumor cells; b) preparing products that inhibit tumor growth; c) preparing products that increase the sensitivity of tumors to PARP inhibitors; d) Preparation of products for tumor treatment.
2. The use according to claim 1, characterized in that: The molar ratio of Olaparib to ML264 is 5-100:0.005-1.
5.
3. The use according to claim 1, characterized in that: The tumor is ovarian cancer.
4. The use according to claim 3, characterized in that: The tumor is resistant ovarian cancer, and the resistant ovarian cancer is ovarian cancer resistant to PARP inhibitors.
5. The use according to claim 1, characterized in that: In the above d), the tumor treatment at least manifests itself in: promoting apoptosis of ovarian cancer tumor tissue and / or prolonging the survival of ovarian cancer patients.
6. The use according to claim 1, characterized in that: The product is a drug or an experimental reagent.
7. A composition, characterized in that The active ingredients of the composition include at least Olaparib and ML264.
8. The composition according to claim 7, characterized in that The molar ratio of Olaparib to ML264 is 5-100:0.005-1.
5.
9. The composition according to claim 7 or 8, characterized in that The composition has any one or more of the following applications: a) Promote apoptosis of tumor cells; b) inhibiting tumor growth; c) Increase tumor sensitivity to PARP inhibitors; d)Tumor treatment.
10. The composition according to claim 9, characterized in that In said d), the tumor treatment at least manifests itself in: promoting apoptosis of ovarian cancer tumor tissue and / or prolonging the survival of ovarian cancer patients; The tumor is ovarian cancer, and further is resistant ovarian cancer, wherein the resistant ovarian cancer is ovarian cancer resistant to PARP inhibitors.
Citation Information
Cited By
Drug application of combination of IDH1 inhibitor and PARP inhibitor
CN119868565A
The application of IDH1 inhibitors combined with PARP inhibitors
CN119868565B
Application of HDAC8 inhibitor in preparation of medicine for enhancing curative effect of PARP inhibitor or reversing / improving drug resistance of PARP inhibitor
CN122031463A
